[1]
|
(2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. https://doi.org/10.3322/caac.21660
|
[2]
|
Pizzato, M., Li, M., Vignat, J., et al. (2022) The Epidemiological Landscape of Thyroid Cancer Worldwide: GLOBOCAN Esti-mates for Incidence and Mortality Rates in 2020. The Lancet Diabetes & Endocrinology, 10, 264-272. https://doi.org/10.1016/S2213-8587(22)00035-3
|
[3]
|
Cabanillas, M.E., McFadden, D.G. and Durante, C. (2016) Thyroid Cancer. The Lancet, 388, 2783-2795.
https://doi.org/10.1016/S0140-6736(16)30172-6
|
[4]
|
Dong, W., Horiuchi, K., Tokumitsu, H., et al. (2019) Time-Varying Pattern of Mortality and Recurrence from Papillary Thyroid Cancer: Lessons from a Long-Term Fol-low-Up. Thyroid, 29, 802-808. https://doi.org/10.1089/thy.2018.0128
|
[5]
|
Liu, C., Xiao, C., Chen, J., et al. (2019) Risk Factor Analysis for Predicting Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 966 Patients. BMC Cancer, 19, Article No. 622.
https://doi.org/10.1186/s12885-019-5835-6
|
[6]
|
Xing, Z., Qiu, Y., Yang, Q., et al. (2020) Thyroid Cancer Neck Lymph Nodes Metastasis: Meta-Analysis of US and CT Diagnosis. European Journal of Radiology, 129, Article No. 109103. https://doi.org/10.1016/j.ejrad.2020.109103
|
[7]
|
Eun, N.L., Son, E.J., Kim, J.-A., et al. (2018) Compari-son of the Diagnostic Performances of Ultrasonography, CT and Fine Needle Aspiration Cytology for the Prediction of Lymph Node Metastasis in Patients with Lymph Node Dissection of Papillary Thyroid Carcinoma: A Retrospective Co-hort Study. International Journal of Surgery, 51, 145-150.
https://doi.org/10.1016/j.ijsu.2017.12.036
|
[8]
|
郭继云. 甲状腺癌超声诊断与病理诊断对比分析[J]. 现代医用影像学, 2017, 26(4): 1071-1073.
|
[9]
|
王洁琼, 万宇, 刘云, 等. 细针穿刺细胞学在甲状腺癌中漏诊误诊原因及临床价值分析[J]. 西部医学, 2023, 35(11): 1572-1576. https://doi.org/10.3969/j.issn.1672-3511.2023.11.003
|
[10]
|
初霞. 甲状腺癌癌前病变的研究进展[J]. 中国实验诊断学, 2013, 17(3): 594-596.
https://doi.org/10.3969/j.issn.1007-4287.2013.03.063
|
[11]
|
Scognamiglio, T. (2017) C Cell and Follicular Epithelial Cell Precursor Lesions of the Thyroid. Archives of Pathology & Laboratory Medicine, 141, 1646-1652. https://doi.org/10.5858/arpa.2016-0399-RA
|
[12]
|
冯娟, 唐磊彬. CK19、HBME-1和Gal-3在PTMC中的表达及意义[J]. 中国卫生标准管理, 2022, 13(23): 66-71.
https://doi.org/10.3969/j.issn.1674-9316.2022.23.016
|
[13]
|
关莹. 甲状腺肿瘤标记物在桥本甲状腺炎及甲状腺乳头状癌中的应用价值分析[J]. 中国医疗器械信息, 2020, 26(13): 153-155. https://doi.org/10.3969/j.issn.1006-6586.2020.13.071
|
[14]
|
林茂华, 毛瑛玉, 李婷, 等. CK19、CyclinD1、HBME-1、34βE12、TPO、galectin-3在甲状腺乳头状癌组织中的表达及意义[J]. 实用癌症杂志, 2013, 28(6): 617-619. https://doi.org/10.3969/j.issn.1001-5930.2013.06.012
|
[15]
|
许文琼, 梅金红, 汤佳珍, 等. Galectin-3、HBME-1和VEGF在甲状腺乳头状癌的表达及诊断意义[J]. 中国现代医学杂志, 2015, 25(18): 26-30.
|
[16]
|
佟杰, 王岩, 笪冀平. CK19、HBME-1、Galectin-3等表达在甲状腺乳头状微小癌与良性病变鉴别诊断中的意义[J]. 中华肿瘤杂志, 2011, 33(8): 599-604. https://doi.org/10.3760/cma.j.issn.0253-3766.2011.08.010
|
[17]
|
Aydın, K., Ersöz Gülçelik, N., Tuncel, M., et al. (2019) Thyroid Volumes and Serum VEGF Levels in Dyslipidemic Patients: Ef-fects of Statin Treatment. Turkish Journal of Medical Sciences, 49, 738-745.
https://doi.org/10.3906/sag-1708-106
|
[18]
|
曹力钒. Survivin与VEGF因子在甲状腺癌中的表达及其临床意义[J]. 实用癌症杂志, 2021, 36(8): 1253-1255.
https://doi.org/10.3969/j.issn.1001-5930.2021.08.010
|
[19]
|
白建平, 张霆, 秦大伟. Livin和VEGF在甲状腺癌中的表达及与临床病理因素的相关性[J]. 中国老年学杂志, 2014(16): 4485-4487. https://doi.org/10.3969/j.issn.1005-9202.2014.16.033
|
[20]
|
Nangia-Makker, P., Hogan, V. and Raz, A. (2018) Galectin-3 and Cancer Stemness. Glycobiology, 28, 172-181.
https://doi.org/10.1093/glycob/cwy001
|
[21]
|
Cymbaluk-Płoska, A., Gargulińska, P., Kwiatkowski, S., et al. (2020) Could Galectin 3 Be a Good Prognostic Factor in Endometrial Cancer? Diagnostics (Basel), 10, Article No. 635. https://doi.org/10.3390/diagnostics10090635
|
[22]
|
刘星, 霍占江. 甲状腺乳头状癌组织中galecti-3与miR-375水平表达意义及相关性研究[J]. 现代检验医学杂志, 2023, 38(1): 49-52, 185. https://doi.org/10.3969/j.issn.1671-7414.2023.01.010
|
[23]
|
Giannini, R., Faviana, P., Cavinato, T., et al. (2003) Galectin-3 and Oncofetal-Fibronectin Expression in Thyroid Neoplasia as Assessed by Reverse Transcrip-tion-Polymerase Chain Reaction and Immunochemistry in Cytologic and Pathologic Specimens. Thyroid, 13, 765-770. https://doi.org/10.1089/105072503768499662
|
[24]
|
焦志波. 桥本氏甲状腺炎合并甲状腺微小乳头状癌与甲状腺微小乳头状癌临床病理特征的相关研究[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2019.
|
[25]
|
张婵. CK19、TTF-1、VEGF联合检测在甲状腺癌组织中的表达及临床意义[D]: [硕士学位论文]. 邯郸: 河北工程大学, 2020.
|
[26]
|
Calangiu, C.M., Simionescu, C.E., Stepan, A.E., et al. (2014) The Expression of CK19, Vimentin and E-cadherin in Differentiated Thyroid Carcinomas. Romanian Journal of Morphology and Embryology, 55, 919-925.
|
[27]
|
Alshenawy, H.A. (2014) Utility of Immunohistochemical Markers in Diagnosis of Follicular Cell De-rived Thyroid Lesions. Pathology and Oncology Research, 20, 819-828. https://doi.org/10.1007/s12253-014-9760-3
|
[28]
|
Huang, L., Wang, X., Huang, X., et al. (2018) Diagnostic Signif-icance of CK19, Galectin-3, CD56, TPO and Ki67 Expression and BRAF Mutation in Papillary Thyroid Carcinoma. Oncology Letters, 15, 4269-4277.
https://doi.org/10.3892/ol.2018.7873
|
[29]
|
Li, C., Yuan, J., Zhu, Y.-F., et al. (2016) Imbalance of Th17/Treg in Different Subtypes of Autoimmune Thyroid Diseases. Cellular Physiology and Biochemistry, 40, 245-252. https://doi.org/10.1159/000452541
|
[30]
|
Elkord, E., Alcantar-Orozco, E.M., Dovedi, S.J., et al. (2010) T Regulato-ry Cells in Cancer: Recent Advances and Therapeutic Potential. Expert Opinion on Biological Therapy, 10, 1573-1586.
https://doi.org/10.1517/14712598.2010.529126
|
[31]
|
Nishikawa, H. and Sakaguchi, S. (2014) Regulatory T Cells in Cancer Immunotherapy. Current Opinion in Immunology, 27, 1-7. https://doi.org/10.1016/j.coi.2013.12.005
|
[32]
|
Núñez, N.G., Tosello Boari, J., Ramos, R.N., et al. (2020) Tumor Invasion in Draining Lymph Nodes Is Associated with Treg Accumulation in Breast Cancer Patients. Nature Communi-cations, 11, Article No. 3272.
https://doi.org/10.1038/s41467-020-17046-2
|
[33]
|
Whiteside, T.L. (2012) What Are Regulatory T Cells (Treg) Regulating in Cancer and Why? Seminars in Cancer Biology, 22, 327-334. https://doi.org/10.1016/j.semcancer.2012.03.004
|
[34]
|
Michel, S., Benner, A., Tariverdian, M., et al. (2008) High Density of FOXP3-Positive T Cells Infiltrating Colorectal Cancers with Microsatellite Instability. British Journal of Cancer, 99, 1867-1873.
https://doi.org/10.1038/sj.bjc.6604756
|
[35]
|
Ugolini, C., Elisei, R., Proietti, A., et al. (2014) FoxP3 Expression in Papillary Thyroid Carcinoma: A Possible Resistance Biomarker to Iodine 131 Treatment. Thyroid, 24, 339-346. https://doi.org/10.1089/thy.2012.0589
|
[36]
|
Ma, S., Wang, Q., Ma, X., et al. (2016) FoxP3 in Papillary Thyroid Carcinoma Induces NIS Repression through Activation of the TGF-β1/Smad Signaling Pathway. Tumor Biology, 37, 989-998.
https://doi.org/10.1007/s13277-015-3848-6
|
[37]
|
Zhang, X., Guo, M., Yang, J., et al. (2019) Increased Expression of GARP in Papillary Thyroid Carcinoma. Endocrine Pathology, 30, 1-7. https://doi.org/10.1007/s12022-018-9557-0
|
[38]
|
French, J.D., Weber, Z.J., Fretwell, D.L., et al. (2010) Tu-mor-Associated Lymphocytes and Increased FoxP3+ Regulatory T Cell Frequency Correlate with More Aggressive Pa-pillary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism, 95, 2325-2333. https://doi.org/10.1210/jc.2009-2564
|
[39]
|
Liu, Y., Yun, X., Gao, M., et al. (2015) Analysis of Regulatory T Cells Frequency in Peripheral Blood and Tumor Tissues in Papillary Thyroid Carcinoma with and without Hashimoto’s Thy-roiditis. Clinical and Translational Oncology, 17, 274-280. https://doi.org/10.1007/s12094-014-1222-6
|
[40]
|
王敏, 姜藻. CD44与肿瘤关系的研究进展[J]. 国际肿瘤学杂志, 2009, 36(8): 579-582.
https://doi.org/10.3760/cma.j.issn.1673-422X.2009.08.007
|
[41]
|
肖志远, 宋冰, 马鑫雨, 等. 细胞凋亡相关基因CD44在甲状腺癌组织中的表达及其与肿瘤侵袭和免疫细胞浸润关系的生物信息学分析[J]. 吉林大学学报(医学版), 2023, 49(2): 473-481.
https://doi.org/10.13481/j.1671-587X.20230224
|
[42]
|
Figge, J., del Rosario, A.D., Gerasimov, G., et al. (1994) Preferential Expression of the Cell Adhesion Molecule CD44 in Papillary Thyroid Carcinoma. Experimental and Molec-ular Pathology, 61, 203-211.
https://doi.org/10.1006/exmp.1994.1037
|
[43]
|
Böhm, J.P., Niskanen, L.K., Pirinen, R.T., et al. (2000) Reduced CD44 Standard Expression Is Associated with Tumour Recurrence and Unfavourable Outcome in Differentiated Thyroid Carcinoma. The Journal of Pathology, 192, 321-327. https://doi.org/10.1002/1096-9896(2000)9999:9999<::AID-PATH711>3.0.CO;2-1
|
[44]
|
Cornetta, A.J., Russell, J.P., Cunnane, M., et al. (2002) Cyclooxygenase-2 Expression in Human Thyroid Carcinoma and Hashimoto’s Thyroidi-tis. Laryngoscope, 112, 238-242. https://doi.org/10.1097/00005537-200202000-00008
|
[45]
|
Gipsyianti, N., Aziz, A., Hernowo, B.S., et al. (2021) High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF-β1. Clinical, Cosmetic and Investigational Dermatology, 14, 209-216.
https://doi.org/10.2147/CCID.S285564
|
[46]
|
马西, 杜鹏程, 宁登, 等. IL-13、COX2和PI3 K/Akt信号通路与结肠癌侵袭转移的关系[J]. 广东医学, 2020, 41(16): 1637-41. https://doi.org/10.13820/j.cnki.gdyx.20200666
|
[47]
|
胡玮, 尚培中, 李伟, 等. 甲状腺乳头状癌CK19和COX-2表达的临床病理研究[J]. 中华内分泌外科杂志, 2022, 16(4): 436-40. https://doi.org/10.3760/cma.j.cn.115807-20210203-00042
|
[48]
|
Lo, C.-Y., Lam, K.-Y., Leung, P.P., et al. (2005) High Prevalence of Cyclooxygenase 2 Expression in Papillary Thyroid Carcinoma. European Journal of Endocrinology, 152, 545-550. https://doi.org/10.1530/eje.1.01883
|